Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News PAVmed Inc PAVM

Alternate Symbol(s): PAVMZ

Healthcare Medical Devices

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device... see more

Add To Watchlist

Recent & Breaking News (NDAQ:PAVM)

PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference

PR Newswire September 21, 2023

Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection

PR Newswire September 7, 2023

Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters

PR Newswire September 6, 2023

Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit

PR Newswire August 24, 2023

PAVmed Provides Business Update and Second Quarter Financial Results

PR Newswire August 15, 2023

Lucid Diagnostics Provides Business Update and Second Quarter Financial Results

PR Newswire August 14, 2023

PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023

PR Newswire July 31, 2023

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023

PR Newswire July 31, 2023

Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference

PR Newswire July 26, 2023

PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Coverage

PR Newswire July 19, 2023

PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire June 28, 2023

PAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLC

PR Newswire June 14, 2023

Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit

PR Newswire June 5, 2023

PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member

PR Newswire June 2, 2023

PAVmed Provides Business Update and First Quarter Financial Results

PR Newswire May 16, 2023

Lucid Diagnostics Provides Business Update and First Quarter Financial Results

PR Newswire May 15, 2023

Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference

PR Newswire May 11, 2023

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023

PR Newswire May 5, 2023

PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023

PR Newswire May 5, 2023

PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President

PR Newswire April 25, 2023